Allara $10 Million in Series A Funding, Led by GV


Allara, a trailblazing virtual care platform addressing the unmet needs of millions of women dealing with chronic hormonal conditions, has successfully raised $10 million in Series A funding.

The funding round was lead by GV and saw participation from notable investors including Great Oaks Venture Capital, Humbition, Vanterra, Gaingels, as well as individual backers like Tom Lee (One Medical) and Maggie Sellers. GV General Partner Frédérique Dame has joined Allara’s Board of Directors.

Allara’s innovative care platform is designed to bridge the care gap for women of reproductive age struggling with chronic hormonal conditions. By connecting patients with expert doctors and registered dietitians, Allara provides ongoing, specialized care, addressing a significant void in women’s healthcare.

Over the past year, Allara has experienced remarkable growth, expanding its patient base fivefold. The platform has also established in-network status with major insurers across eight states, covering 30 million lives. Allara plans to extend its insurance coverage, forge partnerships with leading health systems for seamless patient care, and conduct essential clinical research with the newly acquired funds.

Rachel Blank, a digital health veteran and founder of Allara, created the platform after her own challenges in navigating a PCOS diagnosis without adequate medical support.

Commenting on Allara’s mission, Blank stated,

“Women’s health is often misconceived as limited to pregnancy and fertility, disregarding the intricate web of health conditions impacting women’s daily lives and long-term health. At Allara, we alleviate the burden on patients to navigate a fragmented care system and empower them with a comprehensive, preventative approach to their health. We are grateful for the support of GV and our dedicated partners to scale our operations and extend this vital care offering to women nationwide.”

Chronic conditions such as polycystic ovary syndrome (PCOS), endometriosis, and hypothyroidism affect more than one in three women. Despite their prevalence, many women endure years of suffering, remaining undiagnosed for as long as a decade.

These conditions often lead to complications such as infertility, high-risk pregnancies, obesity, and diabetes. Delayed diagnoses and treatments also result in significant costs to the healthcare system. Allara aims to address these gaps by providing women with chronic conditions the specialized care they need, ensuring they feel seen, heard, and supported.

Frédérique Dame, GV General Partner, commended Allara’s commitment to elevating hormonal healthcare for women of reproductive age. Dame stated, “Allara raises the bar for clinically driven, personalized hormonal healthcare. The platform has built a brand and community that hundreds of thousands of patients trust, and we’re excited to support CEO Rachel Blank and the team as they provide women with compassionate, modern healthcare.”

This significant funding positions Allara at the forefront of transforming women’s healthcare, emphasizing the company’s dedication to delivering personalized, empathetic, and specialized care for women dealing with chronic hormonal conditions.

Related Stories